The General Hospital Corporation

Xin Hong

Daniel Arie Haber

Shyamala Maheswaran

David Tomoaki Miyamoto

Tanya Todorova

Mark Kalinich

Mehmet Toner

Ravi Kapur

Sarah Javaid

Tanya Todorova Kwan

This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.

Digital analysis of circulating tumor cells in blood samples

Growing community of inventors

Medford, MA, United States of America

Xin Hong